AAPL 192.14 -3.2 (-1.64%)MSFT 117.58 -2.46 (-2.05%)FB 164.73 -1.32 (-0.79%)ZNGA 5.3 -0.13 (-2.31%)NVDA 177.26 -6.63 (-3.61%)WBA 62.56 -1.01 (-1.59%)GOOG 1205.94 -25.16 (-2.04%)PIH 5.45 -0.16 (-2.85%)
AAPL 192.14 -3.2 (-1.64%)MSFT 117.58 -2.46 (-2.05%)FB 164.73 -1.32 (-0.79%)ZNGA 5.3 -0.13 (-2.31%)NVDA 177.26 -6.63 (-3.61%)WBA 62.56 -1.01 (-1.59%)GOOG 1205.94 -25.16 (-2.04%)PIH 5.45 -0.16 (-2.85%)

Financial Statements CRSP Quote CRISPR Ther

All | Income Statement | Balance Sheet | Cash Flow | Retained Earnings | PPE Schedule | Intangible and Goodwill Schedule
Income Statement
Year 201420152016
Revenue 0 5 41
COGS 0 0 0
GrossProfit 0 5 41
Depreciation (included in COGS) 0 1 3
StockBasedCompe (included in COGS) 4 11 19
ResearchAndDeve 13 42 70
SalesGeneralAnd 13 31 36
OperatingIncome -26 -68 -65
InterestExpense 0 8 0
OtherIncome 0 53 -2
IncomeBeforeTax -26 -23 -67
ProvisionForInc 0 0 0
NetIncome -26 -23 -68
Balance Sheet
Year 201420152016
CashAndCashEqui 156 316 240
ShortTermInvest 0 0 0
Cash 156 316 240
AccountReceivab 0 2 3
Inventories 0 0 0
DeferredIncomeT 0 0 0
OtherCurrentAss 0 1 0
TotalCurrentAss 157 320 248
PPE 1 22 23
AccumulatedDepr 0 -1 -4
NetPPE 1 21 19
EquityAndOtherI 0 0 0
Goodwill 0 0 0
IntangibleAsset 0 0 0
OtherLTAssets 1 3 4
TotalNonCurrent 3 25 23
TotalAssets 159 345 271
ShortTermDebt 0 0 0
AccountsPayable 2 5 2
TaxesPayable 0 0 0
AccruedLiabilit 8 16 11
DeferredRevenue 75 78 57
OtherCurrentLia 0 1 1
TotalCurrentLia 10 22 15
Debt 38 0 0
DeferredTaxesLi 0 0 0
DeferredRevenue 0 0 0
OtherLTLiabilit 65 12 12
TotalNonCurrent 178 90 69
TotalLiabilitie 189 112 84
CommonStock 0 1 1
AdditionalPaidI 5 289 312
RetainedEarning -34 -57 -125
AccumulatedOthe 0 0 0
TotalStockholde -29 233 188
TotalLiabilitie 159 345 271
Cash Flow Statement
Year 201420152016
NetIncome -26 -23 -68
Depreciation 0 1 3
DeferredIncomeT 0 0 0
StockBasedCompe 4 11 19
AccountsReceiva 0 -3 1
InventoryCS 0 0 0
AccountsPayable 0 0 0
OtherWorkingCap 82 6 -22
OtherNonCashIte 0 -46 2
NetCashProvided 59 -55 -70
InvestmentsInPP -1 -3 -8
AcquisitionsNet 0 0 0
PurchasesOfInve 0 0 0
SalesMaturities 0 0 0
PurchasesOfInta 0 0 0
OtherInvestingA 0 35 0
NetCashUsedForI -1 32 -8
DebtIssued 38 35 0
DebtRepayment 0 0 0
CommonStockIssu 0 89 0
CommonStockRepu 0 0 0
DividendPaid 0 0 0
OtherFinancingA 0 -2 3
NetCashProvided 97 183 3
NetChangeInCash 155 160 -76
CashAtBeginning 1 156 316
CashAtEndOfPeri 156 316 240
Retained Earnings
Year 201420152016
RetainedEarning ---8
NetIncome --6-26
StockDividend -1452
DividendPaid ---
RetainedEarning --8-34
Property Plant and Equipment Schedule
Year 201420152016
NetPPE ---
DeprAnnual 0--
CapitalExpendit 001
NetPPE --1
Intangible and Goodwill Schedule
Year 201420152016
intAndGW 0-1
Amortization 0--
NewPurchases 01-1
intAndGW -1-
CRISPR Therapeutics AG income statement is the only one that provides an overview of company sales and net income
The reasoning behind the adjustment, however, is that free cash flow is meant to measure money being spent right now, not transactions that happened in the past. This makes CRISPR Therapeutics AG FCF a useful instrument for identifying growing companies with high up-front costs, which may eat into earnings now but have the potential to pay off later.